Results 81 to 90 of about 615,884 (310)

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

Biological functions and molecular mechanisms of LINC00961 in human cancer

open access: yesAll Life, 2023
Long non-coding RNAs (lncRNAs) are more than 200 bp in length and do not translate into functional proteins. They are involved in inhibiting cell growth, migration, and invasion, and in promoting apoptosis.
Kai Li   +3 more
doaj   +1 more source

Plasma microRNA Associated with EGFR-TKI Primary Resistance in Non-Small Cell Lung Cancer with EGFR-Mutation [PDF]

open access: yes, 2016
背景 肺癌是目前全世界范围内发病率和死亡率较高的恶性肿瘤之一。按组织学分类,肺癌可以分为两大类:小细胞肺癌(smallcelllungcancer,SCLC)和非小细胞肺癌(nonsmallcelllungcancer,NSCLC),小细胞肺癌占所有病例的20%,其余80%左右为NSCLC,包括鳞癌、腺癌、大细胞癌等类型。手术、放疗以及化疗等多学科综合治疗是指南推荐的NSCLC的首选治疗方式。由于NSCLC早期的典型临床症状和体征并不明显,约2/3的NSCLC患者在确诊时已发展为中晚期,失去手术根治机会。
潘小艳
core  

Preoperative CYFRA 21-1 and CEA as Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer [PDF]

open access: yes, 2008
Objective: To validate the prognostic value of preoperative levels of CYFRA 21-1, CEA and the corresponding tumor marker index (TMI) in patients with stage I non-small cell lung cancer (NSCLC). Methods: Two hundred forty stage I NSCLC patients (80 in pT1
Ankerst, Donna Pauler   +7 more
core   +1 more source

TTF-1/p63-positive poorly differentiated NSCLC: A histogenetic hypothesis from the basal reserve cell of the terminal respiratory unit [PDF]

open access: yes, 2020
TTF-1 is expressed in the alveolar epithelium and in the basal cells of distal terminal bronchioles. It is considered the most sensitive and specific marker to define the adenocarcinoma arising from the terminal respiratory unit (TRU). TTF-1, CK7, CK5/6,
Barraco N.   +8 more
core   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]

open access: yes, 2007
We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross   +2 more
core   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. [PDF]

open access: yes, 2020
Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy is limited to certain tumors and would benefit from identifying a biomarker predictive of therapeutic response.
Boichard, Amélie   +2 more
core  

Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]

open access: yes, 2018
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy